Spexy Beast

Spexis Announces Changes to the Executive Committee

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Railway Executive Committee, Trust, LR, Allschwil, Rare, Executive Committee, Therapy, Human resources, Management, Spexy Beast

Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023. Martin Jakobovic, currently Head of Finance, will succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023. Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.

Key Points: 
  • He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023.
  • Martin Jakobovic, currently Head of Finance, will succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023.
  • Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.
  • “I would like to thank Jeff, the board of directors, our shareholders, and the entire Spexis team for their trust, support, and commitment.

Spexis to host business update conference call on October 9, 2023

Retrieved on: 
Tuesday, October 17, 2023
Therapy, Rare, Cryptocurrency, Spexy Beast

Spexis to host business update conference call on October 9, 2023

Key Points: 
  • Spexis to host business update conference call on October 9, 2023
    Spexis to host business update conference call on October 9, 2023
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.
  • Jeffrey D. Wager, M.D.
  • (CEO & Chairman) will provide strategic business and financial updates.
  • To access the conference call please use the following details:

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute for Materials Research and Testing, Pharmaceutical industry, Fine chemical, Nursing, Spexy Beast

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Key Points: 
  • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute of Science and Technology, Fine chemical, Pharmaceutical industry, Nursing, Spexy Beast

ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Key Points: 
  • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Retrieved on: 
Tuesday, August 15, 2023
Therapy, LR, COPA, USD, Cystic fibrosis, Rare, SGI, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023. The USD $2.5 million capital commitment will be in the form of USD $1.0 million in secured, interest-bearing debt with partial warrant coverage from SGI and USD $1.5 million subordinated debt mandatorily converting into equity from institutional investors.

Key Points: 
  • 53 LR
    ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.
  • The USD $2.5 million capital commitment will be in the form of USD $1.0 million in secured, interest-bearing debt with partial warrant coverage from SGI and USD $1.5 million subordinated debt mandatorily converting into equity from institutional investors.
  • “This additional commitment from SPRIM demonstrates their continued support for the clinical development of ColiFin®, our inhaled macrocycle therapeutic for the management of chronic infections in cystic fibrosis patients” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “This new capital allows us to not only initiate the COPILOT study in the third quarter, but will also allow for continued progress across start-up activities for COPA, the second part of our planned pivotal efficacy and safety Phase 3 study.”

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Retrieved on: 
Friday, June 30, 2023
LR, Research, COPA, MD, M & A, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities. Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program through the planned single pivotal efficacy and safety COPA study following the completion of the COPILOT once-a-day dosing, safety and tolerability clinical trial.

Key Points: 
  • 53 LR
    ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities.
  • Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program through the planned single pivotal efficacy and safety COPA study following the completion of the COPILOT once-a-day dosing, safety and tolerability clinical trial.
  • Maxim Group LLC is a full-service investment banking firm headquartered in New York with approximately 240 employees.
  • Maxim Group provides a full array of financial services, including investment banking; private wealth management; and global institutional equity, fixed-income, and derivatives sales and trading, as well as equity research.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Retrieved on: 
Saturday, June 10, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Antibiotics, Vaccine, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • Recent discovery of plasmid-mediated transferable colistin resistance genes have shown the ease with which resistance can spread in bacterial populations.
  • No cross-resistance with standard of care antibiotics was observed and the demonstrated Enterobacteriaceae-specificity versus broad-spectrum activity supports continued development for this class of antibiotics for the potential management and treatment of antimicrobial resistant pathogens.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carba

Retrieved on: 
Wednesday, June 7, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Vaccine, Antibiotics, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • Antimicrobial resistance (AMR) has emerged as a significant threat for both patients and healthcare systems.
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • The compounds showed potent in vivo efficacy, especially in lung infection models as well as a promising in vitro and in vivo safety profile.

Spexis provides business update and announces financial results for the full year 2022

Retrieved on: 
Tuesday, May 30, 2023
Partnership, Inhalation, QIDP, Clinical trial, LR, Pharmacokinetics, Research, Bronchiectasis, COPA, BLX, USD, Transplant, Pseudomonas aeruginosa, Plasma, Kidney, Bone marrow, Patient, Collection, Lower respiratory tract infection, Cystic fibrosis, Adolescence, MPV, Mortality, Growth, R, Urinary tract infection, FDA, Letter, CHF, SGI, CF, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, May 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced its financial results for the full year of 2022 and provided a strategic business update.

Key Points: 
  • Spexis has worldwide rights to ColiFin® ex-Europe and is focused on developing the product first for the U.S. market.
  • Spexis announced positive results from the Phase 1 clinical trial of balixafortide (BLX) in patients with renal impairment in September 2022.
  • In January 2023, Spexis reported promising safety and pharmacokinetics results from a first-in-human study with inhaled murepavadin (iMPV), a novel macrocycle compound.
  • Spexis’ cash position as of December 31, 2022 was CHF 1.8 million (cash and cash equivalents).

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Retrieved on: 
Tuesday, April 18, 2023
Partnership, QIDP, Clinical trial, LR, COPA, MD, Patient, Cystic fibrosis, SGI, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has finalized a capital commitment from SPRIM Global Investments (SGI) totaling USD 4.5 million in the form of secured, interest-bearing debt with partial warrant coverage and subordinated debt mandatorily converting into equity. Proceeds from the capital commitment will enable the initiation of the Phase 3 COPILOT study, the first part of the registrational clinical studies planned for ColiFin®. The COPILOT study, which will enroll 38 patients and evaluate and confirm the use of once or twice daily dosing for COPA, the second part of the planned pivotal efficacy and safety Phase 3 study of ColiFin®, has study start-up activities ongoing, and is expected to enroll its first patient in June 2023.

Key Points: 
  • Proceeds from the capital commitment will enable the initiation of the Phase 3 COPILOT study, the first part of the registrational clinical studies planned for ColiFin®.
  • The clinical development of ColiFin® is supported by FDA Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track Designations.
  • In addition, and as part of an ongoing strategic realignment, two members of Spexis’ executive committee will be transitioning out of the company.
  • Stephan Wehselau, currently Chief Operating Officer, will be leaving Spexis by the end of June.